{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T11:52:58Z","timestamp":1661255578962},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,10,31]],"date-time":"2016-10-31T00:00:00Z","timestamp":1477872000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s00108-016-0149-0","type":"journal-article","created":{"date-parts":[[2016,10,31]],"date-time":"2016-10-31T03:17:07Z","timestamp":1477883827000},"page":"1182-1190","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clostridium-difficile-Infektion"],"prefix":"10.1007","volume":"57","author":[{"given":"A.","family":"Stallmach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,31]]},"reference":[{"key":"149_CR1","doi-asserted-by":"crossref","first-page":"e98400","DOI":"10.1371\/journal.pone.0098400","volume":"9","author":"CN Abou Chakra","year":"2014","unstructured":"Abou Chakra CN, Pepin J, Sirard S et\u00a0al (2014) Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLOS ONE 9:e98400","journal-title":"PLOS ONE"},{"key":"149_CR2","doi-asserted-by":"crossref","first-page":"758","DOI":"10.7326\/0003-4819-145-10-200611210-00008","volume":"145","author":"JG Bartlett","year":"2006","unstructured":"Bartlett JG (2006) Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 145:758\u2013764","journal-title":"Ann Intern Med"},{"key":"149_CR3","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/infdis\/136.5.701","volume":"136","author":"JG Bartlett","year":"1977","unstructured":"Bartlett JG, Onderdonk AB, Cisneros RL et al (1977) Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J\u00a0Infect Dis 136:701\u2013705","journal-title":"J Infect Dis"},{"key":"149_CR4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40121-014-0050-x","volume":"3","author":"NS Britt","year":"2014","unstructured":"Britt NS, Steed ME, Potter EM et\u00a0al (2014) Tigecycline for the treatment of severe and severe complicated Clostridium difficile infection. Infect Dis Ther 3:321\u2013331","journal-title":"Infect Dis Ther"},{"key":"149_CR5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nature13828","volume":"517","author":"CG Buffie","year":"2015","unstructured":"Buffie CG, Bucci V, Stein RR et\u00a0al (2015) Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517:205\u2013208","journal-title":"Nature"},{"key":"149_CR6","doi-asserted-by":"crossref","first-page":"e0144604","DOI":"10.1371\/journal.pone.0144604","volume":"10","author":"JW Cheng","year":"2015","unstructured":"Cheng JW, Xiao M, Kudinha T et\u00a0al (2015) The role of Glutamate Dehydrogenase (GDH) testing assay in the diagnosis of Clostridium difficile infections: a high sensitive screening test and an essential step in the proposed laboratory diagnosis workflow for developing countries like China. PLOS ONE 10:e0144604","journal-title":"PLOS ONE"},{"key":"149_CR7","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","volume":"12","author":"OA Cornely","year":"2012","unstructured":"Cornely OA, Crook DW, Esposito R et al (2012) Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 12:281\u2013289","journal-title":"Lancet Infect Dis"},{"key":"149_CR8","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/jac\/dkt013","volume":"68","author":"SB Debast","year":"2013","unstructured":"Debast SB, Bauer MP, Sanders IM et al (2013) Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications. J\u00a0Antimicrob Chemother 68:1305\u20131311","journal-title":"J Antimicrob Chemother"},{"key":"149_CR9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijantimicag.2015.03.012","volume":"46","author":"S Bella di","year":"2015","unstructured":"di Bella S, Nisii C, Petrosillo N (2015) Is tigecycline a suitable option for Clostridium difficile infection? Evidence from the literature. Int J Antimicrob Agents 46:8\u201312","journal-title":"Int J Antimicrob Agents"},{"key":"149_CR10","doi-asserted-by":"crossref","first-page":"e000038","DOI":"10.1136\/bmjgast-2015-000038","volume":"2","author":"LT Erikstrup","year":"2015","unstructured":"Erikstrup LT, Aarup M, Hagemann-Madsen R et al (2015) Treatment of Clostridium difficile infection in mice with vancomycin alone is as effective as treatment with vancomycin and metronidazole in combination. BMJ Open Gastroenterol 2:e000038","journal-title":"BMJ Open Gastroenterol"},{"key":"149_CR11","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/00004836-200405000-00005","volume":"38","author":"A Fernandez","year":"2004","unstructured":"Fernandez A, Anand G, Friedenberg F (2004) Factors associated with failure of metronidazole in Clostridium difficile-associated disease. J\u00a0Clin Gastroenterol 38:414\u2013418","journal-title":"J Clin Gastroenterol"},{"key":"149_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/mcg.0000000000000511","author":"L Furuya-Kanamori","year":"2016","unstructured":"Furuya-Kanamori L, Doi SA, Paterson DL et al (2016) Upper versus lower gastrointestinal delivery for transplantation of fecal microbiota in recurrent or refractory Clostridium difficile infection: a collaborative analysis of individual patient data from 14 studies. J\u00a0Clin Gastroenterol. doi: 10.1097\/mcg.0000000000000511","journal-title":"J Clin Gastroenterol"},{"key":"149_CR13","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1086\/657398","volume":"51","author":"KW Garey","year":"2010","unstructured":"Garey KW, Jiang ZD, Ghantoji S et al (2010) A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection. Clin Infect Dis 51:1406\u20131410","journal-title":"Clin Infect Dis"},{"key":"149_CR14","first-page":"916826","volume":"2014","author":"M Goudarzi","year":"2014","unstructured":"Goudarzi M, Seyedjavadi SS, Goudarzi H et\u00a0al (2014) Clostridium difficile infection: epidemiology, pathogenesis, risk factors, and therapeutic options. Scientifica (Cairo) 2014:916826","journal-title":"Scientifica (Cairo)"},{"key":"149_CR15","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1055\/s-0034-1399337","volume":"53","author":"S Hagel","year":"2015","unstructured":"Hagel S, Epple HJ, Feurle GE et al (2015) S2k-guideline gastrointestinal infectious diseases and Whipple\u2019s disease. Z Gastroenterol 53:418\u2013459","journal-title":"Z Gastroenterol"},{"key":"149_CR16","first-page":"583","volume":"113","author":"S Hagel","year":"2016","unstructured":"Hagel S, Fischer A, Ehlermann P et\u00a0al (2016) Fecal microbiota transplant in patients with recurrent Clostridium difficile infection \u2013 a retrospective multicenter observational study from the MicroTrans registry. Dtsch Arztebl Int 113:583\u2013539","journal-title":"Dtsch Arztebl Int"},{"key":"149_CR17","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.4049\/jimmunol.1003761","volume":"186","author":"M Hasegawa","year":"2011","unstructured":"Hasegawa M, Yamazaki T, Kamada N et al (2011) Nucleotide-binding oligomerization domain 1 mediates recognition of Clostridium difficile and induces neutrophil recruitment and protection against the pathogen. J\u00a0Immunol 186:4872\u20134880","journal-title":"J Immunol"},{"key":"149_CR18","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/tid.12267","volume":"16","author":"AM Huang","year":"2014","unstructured":"Huang AM, Marini BL, Frame D et\u00a0al (2014) Risk factors for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients. Transpl Infect Dis 16:744\u2013750","journal-title":"Transpl Infect Dis"},{"key":"149_CR19","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1128\/IAI.00448-12","volume":"80","author":"I Jarchum","year":"2012","unstructured":"Jarchum I, Liu M, Shi C et al (2012) Critical role for MyD88-mediated neutrophil recruitment during Clostridium difficile colitis. Infect Immun 80:2989\u20132996","journal-title":"Infect Immun"},{"key":"149_CR20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/cid\/ciu313","volume":"59","author":"S Johnson","year":"2014","unstructured":"Johnson S, Louie TJ, Gerding DN et\u00a0al (2014) Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 59:345\u2013354","journal-title":"Clin Infect Dis"},{"key":"149_CR21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1056\/NEJM199401273300406","volume":"330","author":"CP Kelly","year":"1994","unstructured":"Kelly CP, Pothoulakis C, LaMont JT (1994) Clostridium difficile colitis. N Engl J Med 330:257\u2013262","journal-title":"N Engl J Med"},{"key":"149_CR22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.anaerobe.2015.08.002","volume":"37","author":"N Khanafer","year":"2016","unstructured":"Khanafer N, Barbut F, Eckert C et\u00a0al (2016) Factors predictive of severe Clostridium difficile infection depend on the definition used. Anaerobe 37:43\u201348","journal-title":"Anaerobe"},{"key":"149_CR23","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jhin.2015.11.010","volume":"92","author":"D Knafl","year":"2016","unstructured":"Knafl D, Winhofer Y, Lotsch F et\u00a0al (2016) Tigecycline as last resort in severe refractory Clostridium difficile infection: a case report. J\u00a0Hosp Infect 92:296\u2013298","journal-title":"J Hosp Infect"},{"key":"149_CR24","volume-title":"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology., vol 2015. UpToDate","author":"T Lamont","year":"2015","unstructured":"Lamont T (2015) Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology., vol 2015. UpToDate. http:\/\/www.uptodate.com\/contents\/clostridium-difficile-in-adults-epidemiology-microbiology-and-pathophysiology . Zugegriffen: 13.10.2016"},{"key":"149_CR25","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa1408913","volume":"372","author":"FC Lessa","year":"2015","unstructured":"Lessa FC, Mu Y, Bamberg WM et\u00a0al (2015) Burden of Clostridium difficile infection in the United States. N Engl J Med 372:825\u2013834","journal-title":"N Engl J Med"},{"key":"149_CR26","doi-asserted-by":"crossref","first-page":"e0137252","DOI":"10.1371\/journal.pone.0137252","volume":"10","author":"R Li","year":"2015","unstructured":"Li R, Lu L, Lin Y et al (2015) Efficacy and safety of metronidazole monotherapy versus vancomycin monotherapy or combination therapy in patients with Clostridium difficile infection: a systematic review and meta-analysis. PLOS ONE 10:e0137252","journal-title":"PLOS ONE"},{"key":"149_CR27","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","volume":"364","author":"TJ Louie","year":"2011","unstructured":"Louie TJ, Miller MA, Mullane KM et\u00a0al (2011) Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364:422\u2013431","journal-title":"N Engl J Med"},{"key":"149_CR28","first-page":"723","volume":"111","author":"C L\u00fcbbert","year":"2014","unstructured":"L\u00fcbbert C, John E, von M\u00fcller L (2014) Clostridium-difficile-Infektion: Leitliniengerechte Diagnostik- und Behandlungsoptionen. Dtsch Arztebl Int 111:723\u2013731","journal-title":"Dtsch Arztebl Int"},{"key":"149_CR29","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1017\/ice.2015.54","volume":"36","author":"R Luo","year":"2015","unstructured":"Luo R, Greenberg A, Stone CD (2015) Outcomes of Clostridium difficile infection in hospitalized leukemia patients: a nationwide analysis. Infect Control Hosp Epidemiol 36:794\u2013801","journal-title":"Infect Control Hosp Epidemiol"},{"key":"149_CR30","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1055\/s-0033-1356442","volume":"52","author":"P Lynen Jansen","year":"2014","unstructured":"Lynen Jansen P, Stallmach A, Lohse AW et\u00a0al (2014) Development of gastrointestinal infectious diseases between 2000 and 2012. Z Gastroenterol 52:549\u2013557","journal-title":"Z Gastroenterol"},{"key":"149_CR31","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1517\/13543784.2016.1161025","volume":"25","author":"LV McFarland","year":"2016","unstructured":"McFarland LV (2016) Therapies on the horizon for Clostridium difficile infections. Expert Opin Investig Drugs 25:541\u2013555","journal-title":"Expert Opin Investig Drugs"},{"key":"149_CR32","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1086\/379836","volume":"188","author":"MM Merrigan","year":"2003","unstructured":"Merrigan MM, Sambol SP, Johnson S et al (2003) Prevention of fatal Clostridium difficile-associated disease during continuous administration of clindamycin in hamsters. J\u00a0Infect Dis 188:1922\u20131927","journal-title":"J Infect Dis"},{"key":"149_CR33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12879-016-1501-7","volume":"16","author":"MA Olsen","year":"2016","unstructured":"Olsen MA, Young-Xu Y, Stwalley D et al (2016) The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. Administrative databases. BMC Infect Dis 16:177","journal-title":"BMC Infect Dis"},{"key":"149_CR34","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1001\/jamainternmed.2015.4114","volume":"175","author":"CR Polage","year":"2015","unstructured":"Polage CR, Gyorke CE, Kennedy MA et\u00a0al (2015) Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med 175:1792\u20131801","journal-title":"JAMA Intern Med"},{"key":"149_CR35","unstructured":"Robert Koch-Institut (2016) Clostridium difficile. RKI-Ratgeber f\u00fcr \u00c4rzte https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Merkblaetter\/Ratgeber_Clostridium.html . Zugegriffen: 13.10.2016"},{"key":"149_CR36","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/cid\/civ409","volume":"61","author":"KE Rokas","year":"2015","unstructured":"Rokas KE, Johnson JW, Beardsley JR et\u00a0al (2015) The addition of intravenous metronidazole to oral vancomycin is associated with improved mortality in critically ill patients with Clostridium difficile infection. Clin Infect Dis 61:934\u2013941","journal-title":"Clin Infect Dis"},{"key":"149_CR37","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.2169\/internalmedicine.54.4641","volume":"54","author":"H Shimizu","year":"2015","unstructured":"Shimizu H, Mori M, Yoshimoto N (2015) Clostridium difficile infection is more severe when toxin is detected in the stool than when detected only by a toxigenic culture. Intern Med 54:2155\u20132159","journal-title":"Intern Med"},{"key":"149_CR38","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1080\/14787210.2016.1211931","volume":"14","author":"ET Slayton","year":"2016","unstructured":"Slayton ET, Hay AS, Babcock CK et\u00a0al (2016) New antibiotics in clinical trials for Clostridium difficile. Expert Rev Anti Infect Ther 14:789\u2013800. doi: 10.1080\/14787210.2016.1211931","journal-title":"Expert Rev Anti Infect Ther"},{"key":"149_CR39","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1099\/jmm.0.058479-0","volume":"62","author":"K Solomon","year":"2013","unstructured":"Solomon K, Martin AJ, O\u2019Donoghue C et al (2013) Mortality in patients with Clostridium difficile infection correlates with host pro-inflammatory and humoral immune responses. J\u00a0Med Microbiol 62:1453\u20131460","journal-title":"J Med Microbiol"},{"key":"149_CR40","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1128\/JB.00610-10","volume":"192","author":"JA Sorg","year":"2010","unstructured":"Sorg JA, Sonenshein AL (2010) Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J\u00a0Bacteriol 192:4983\u20134990","journal-title":"J Bacteriol"},{"key":"149_CR41","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/ajg.2013.4","volume":"108","author":"CM Surawicz","year":"2013","unstructured":"Surawicz CM, Brandt LJ, Binion DG et\u00a0al (2013) Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108:478\u2013498 (quiz 499)","journal-title":"Am J Gastroenterol"},{"key":"149_CR42","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1056\/NEJMoa1205037","volume":"368","author":"E Nood van","year":"2013","unstructured":"van Nood E, Vrieze A, Nieuwdorp M et\u00a0al (2013) Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368:407\u2013415","journal-title":"N Engl J Med"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-016-0149-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-016-0149-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-016-0149-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T22:25:28Z","timestamp":1498343128000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-016-0149-0"}},"subtitle":["Was ist gesichert in der Therapie?"],"short-title":[],"issued":{"date-parts":[[2016,10,31]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["149"],"URL":"https:\/\/doi.org\/10.1007\/s00108-016-0149-0","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,31]]}}}